Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 3/20 | 0.35 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316041 | 0.90 | NOTUM (0.46) | NOTUMKDM4EDRD4DRD2DRD3 | |
| SCHEMBL2632882 | 0.83 | NOTUM (0.48) | NOTUMKDM4EDRD4DRD2DRD3 | |
| SCHEMBL17173258 | 0.80 | NOTUM (0.51) | NOTUMKDM4EDRD4DRD2AADAT | |
| SCHEMBL13180753 | 0.79 | DRD2 (0.42) | NOTUMDRD2DRD3CNR1 | |
| SCHEMBL2632953 | 0.79 | NOTUM (0.53) | NOTUMDRD4DRD2DRD3CNR1 | |
| SCHEMBL9914264 | 0.79 | FAAH (0.36) | NOTUMCNR1 | |
| SCHEMBL26650896 | 0.79 | ADRA2C (0.37) | NOTUMKDM4ECNR1HTR2AHRH1 | |
| SCHEMBL24329575 | 0.78 | GABRA1 (0.42) | NOTUMCNR1HTR2A | |
| SCHEMBL20353869 | 0.76 | HTR2C (0.40) | NOTUMDRD4DRD2DRD3CNR1 | |
| SCHEMBL19910605 | 0.76 | CNR1 (0.33) | NOTUMDRD4CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | NOTUM 1676/4885KDM4E 791/4885DRD4 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.